The End Brain Cancer Initiative (Chris Elliott Fund) connects brain tumor patients, caregivers and their families immediately to advanced treatments & clinical trials. Connecting to: 1) TOP Brain Tumor Neurosurgeons, Neuro-oncologists and Specialists in the U.S.; 2) Immunotherapy Vaccines; 3) 2nd, 3rd, 4th opinions; 4) Genomic Profiling/DNA Sequencing; 5) MGMT and Protein Testing
Their mission is: Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatment, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for patients with brain cancer and patients with brain mets.
End Brain Cancer Initiative
At age 39, in the prime of his life and father of two young children, Chris Elliott was diagnosed with terminal brain cancer and given just one year to live. He and his family refused to give up until they found better treatment options outside of standard protocol. Chris enrolled in a groundbreaking Dana Farber Cancer Institute clinical trial and received the latest in brain cancer treatment and fought a two-year battle to beat the disease. In his final months, Chris felt empowered to help others who are diagnosed with brain cancer and he wanted all prospective patients to know all the quality options available, thus the Chris Elliott Fund was formed. More than ten years later, through Dellann Elliott’s hard work and the dedication of countless volunteers & supporters, Chris’ legacy lives on through Chris Elliott Fund.
Guided by Chris’ experiences through diagnosis, treatment and the struggle to navigate a complicated landscape of misinformation, our services are built with a focus on the patient need for immediate access to advanced treatment options upon diagnosis.
Read Chris’s full story here.